Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases

International Journal of Hematology

Volumn 97, Issue 3, 2013, Pages 345-350

  Habe, Koji ^a   Wada, Hideo ^a   Matsumoto, Takeshi ^a   Ohishi, Kohshi ^a   Ikejiri, Makoto ^a   Matsubara, Kimiko ^a   Morioka, Tatsuhiko ^a   Kamimoto, Yuki ^a   Ikeda, Tomoaki ^a   Katayama, Naoyuki ^b   Nobori, Tsutomu ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 glycoprotein I; APL; APS; LA; Thrombosis

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; AUTOIMMUNE DISEASE; BUDD CHIARI SYNDROME; CENTRAL RETINA VEIN OCCLUSION; CEREBRAL SINUS THROMBOSIS; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEART INFARCTION; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; MALE; MATERNAL HYPERTENSION; MICROTHROMBUS; MIDDLE AGED; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; PREGNANCY COMPLICATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; BLOOD; CLINICAL TRIAL; PREGNANCY;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 84887579031     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1277-0     Document Type: Article

References (27)

1. Palomo IG, Segovia FM, Alarcon ML, Fuentes BY, Pereira JG, Rojas A, Forastiero R. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Front Biosci. 2007;12:3093-103.
2. Staub HL, Bertolaccini ML, Munther MA: Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun. Rev. 2012;52:804-10.
3. Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19:406-11.
4. Hughes G. Hughes Syndrome: The antiphospholipid syndrome-a clinical overview. Clin Rev Allergy Immunol. 2007;32:3-12.
5. Chandramouli NB, Rodgers GM. Management of thrombosis in women with antiphospholipid syndrome. Clin Obstet Gynecol. 2001;44:36-47.
6. Boyanovski B, Russeva M, Dobreva G, Ganev V, Mladenova A, Peicheva V, Nikolov K, Baleva M. Protein C Activity in patients with antiphospholipid syndrome. J Clin Rheumatol. 2000;6: 239-43.
7. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170-5.
8. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12:53-7.
9. Samarkos M, Mylona E, Kapsimali V. The role of complement in the antiphospholipid syndrome: A novel mechanism for pregnancy morbidity. Semin Arthritis Rheum. 2012;42:66-9.
10. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376:1498-509.
11. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012;87:75-81.
12. Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16:627-33.
13. Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus. 2005;14:499-504.
14. Kaburaki J, Kuwana M, Ikeda Y: Anti-cardiolipin-beta2-GPI complex antibodies in idiopathic thrombocytopenic purpura. Intern Med. 1998; 37:796.
15. Munoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tassies D, Espinosa G, Lopez-Soto A, Carmona F, Balasch J, Ordinas A, Ingelmo M. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29: 182-90.
16. Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost. 2011;9: 2117-9.
17. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001;86:1327-30.
18. Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631-40.
19. Kandiah DA, Krilis SA. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's viper venom time and dilute kaolin clotting time detect different populations of antibodies in patients with the antiphospholipid syndrome. Thromb Haemost. 1998;80:250-7.
20. Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A, Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with lupus anticoagulant (LA). Thromb Res. 2010;126:150-3.
21. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, Inanc M. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: A prospective cohort study. Blood. 2001;98:1760-4.
22. De Laat B, Derksen RH, Reber G, Musial J, Swadzba J, Bozic B, Cucnik S, Regnault V, Forastiero R, Woodhams BJ, De Groot PG. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies. J Thromb Haemost. 2011;9:149-53.
23. Pengo V. APS-controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127: 51-2.
24. Deng X, Liu X. Reevaluation of predictive value of ACL and anti-2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world. Rheumatol Int. 2012;32:3881-6.
25. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta M, Laura Bertolaccini M: Clinical accuracy for diagnosis of Antiphospholipid Syndrome in SLE: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012;10:2512-8.
26. Nojima J. Advanced clinical laboratory studies in the graduate school of medicine-studies on pathogenic mechanisms of antiphospholipid syndrome. Rinsho Byori. 2009;57:786-92.
27. Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, Oku K, Kon Y, Horita T, Yasuda S, Koike T. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21:1506-14.